↓ Skip to main content

A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis

Overview of attention for article published in Frontiers in immunology, April 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter
16 X users

Readers on

mendeley
68 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis
Published in
Frontiers in immunology, April 2018
DOI 10.3389/fimmu.2018.00798
Pubmed ID
Authors

Vera Marie Kroesen, Paula Rodríguez-Martínez, Eric García, Yaiza Rosales, Jorge Díaz, Montse Martín-Céspedes, Gustavo Tapia, Maria Rosa Sarrias, Pere-Joan Cardona, Cristina Vilaplana

Abstract

An excessive, non-productive host-immune response is detrimental in active, chronic tuberculosis (TB) disease as it typically leads to tissue damage. Given their anti-inflammatory effect, non-steroidal anti-inflammatory drugs can potentially attenuate excessive inflammation in active TB disease. As such, we investigated the prophylactic and therapeutic effect of low-dose aspirin (LDA) (3 mg/kg/day), either alone or in combination with common anti-TB treatment or BCG vaccination, on disease outcome in an experimental murine model of active TB. Survival rate, bacillary load (BL) in lungs, and lung pathology were measured. The possible mechanism of action of LDA on the host's immune response was also evaluated by measuring levels of CD5L/AIM, selected cytokines/chemokines and other inflammatory markers in serum and lung tissue. LDA increased survival, had anti-inflammatory effects, reduced lung pathology, and decreased bacillary load in late-stage TB disease. Moreover, in combination with common anti-TB treatment, LDA enhanced survival and reduced lung pathology. Results from the immunological studies suggest the anti-inflammatory action of LDA at both a local and a systemic level. Our results showed a systemic decrease in neutrophilic recruitment, decreased levels of acute-phase reaction cytokines (IL-6, IL-1β, and TNF-α) at late stage and a delay in the decrease in T cell response (in terms of IFN-γ, IL-2, and IL-10 serum levels) that occurs during the course of Mycobacterium tuberculosis infection. An anti-inflammatory milieu was detected in the lung, with less neutrophil recruitment and lower levels of tissue factor. In conclusion, LDA may be beneficial as an adjunct to standard anti-TB treatment in the later stage of active TB by reducing excess, non-productive inflammation, while enhancing Th1-cell responses for elimination of the bacilli.

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 68 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 18%
Researcher 9 13%
Student > Ph. D. Student 7 10%
Student > Bachelor 7 10%
Student > Doctoral Student 4 6%
Other 11 16%
Unknown 18 26%
Readers by discipline Count As %
Medicine and Dentistry 16 24%
Biochemistry, Genetics and Molecular Biology 7 10%
Immunology and Microbiology 6 9%
Agricultural and Biological Sciences 4 6%
Social Sciences 4 6%
Other 7 10%
Unknown 24 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2018.
All research outputs
#3,544,232
of 25,382,440 outputs
Outputs from Frontiers in immunology
#3,864
of 31,537 outputs
Outputs of similar age
#68,377
of 340,059 outputs
Outputs of similar age from Frontiers in immunology
#121
of 707 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 31,537 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,059 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 707 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.